HOXA9 and chronic myelogenous leukemia, BCR-ABL1 positive: However, for data regarding the proportion of HOXA9 expression in CML and its effect on blastic transformation, HOXA9 should be evaluated in a larger number of patients both at presentation and during blastic crisis, and it will be important to evaluate misexpression of HOXA9 oncogenes when seeking genes involved in the progression of CML to acute myeloid leukemia.